Being one of China’s leading pharmaceutical companies, research and development is our lifeblood as we strive to continually develop efficacious pharmaceutical products that can further enhance the quality of life.

With 80 in-house researchers who have been handpicked for their specialties in different fields, ranging from chemical synthesis, drug formulation and preparation methods to clinical research, product registration, manufacturing techniques and pharmaceutical analysis, C&O is one of the few qualified pharmaceutical companies in China with the expertise to provide contract research services to the growing number of international pharmaceutical companies seeking to outsource their R&D activities to China.

As a testimony to our expertise and leadership position, we have received numerous research grants and awards including the prestigious National 863 Project (for work on a potential Category 1 drug YC-12) under the National High Technology Research Development Program of the PRC government. List of C&O’s Awards

We also collaborate closely with renowned research institutions to tap on their resources and expertise.

With all the necessary building blocks in place – talents, experience, knowledge, recognition and the state-of-the-art equipment and facilities – we are ready to take on greater challenges and scale up our R&D activities. We are in the midst of expanding both R&D centres in Nanjing and in Shanghai to meet the increasing market demand for our R&D work.

To expand our portfolio of proprietary drugs, we are developing a range of drugs that address acute medical areas such as anti-infection, anti-HBV, anti-cancer, anti-tuberculosis, anti-aging and anti-obesity. Three potential category 1 drugs are also under development. (Category 1 drugs are referred as pharmaceutical products that have not been previously approved for sale in China and overseas).